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INTRODUCTION
The growing incidence of overweight and obesity worldwide is a major health concern not only in developed countries, but also in the developing world. [1] [2] [3] The prevalence of a body mass index (BMI) >85 percentile has tripled among children and adolescents since 1980, 2 and over 30% of children are at or above the 85 th percentile. 4 Little is known about the pharmacokinetics of high dose chemotherapy in overweight patients; several reviews have raised the concern about increased toxicity without dose adjustment, or increased relapse risk with dose adjustments for ideal body weight (IBW). 5, 6 Overweight patients may have altered chemotherapy distribution, which may lead to differences in kidney and liver blood flow, with diminished clearance. 5 In the setting of hematopoietic stem cell transplantation (HSCT) complications more common in overweight patients, such as hyperglycemia, have been associated with an increased risk of acute graft vs. host disease (GVHD) and infection, and a subsequent increase in transplant related mortality (TRM). 7, 8 Furthermore, relatively few data are available in pediatric specific populations. To date, there has not been a comprehensive analysis of the risks of treatment related mortality and relapse in over and underweight pediatric patients receiving hematopoietic stem cell transplant (HSCT).
The extrapolation of adult data to pediatric populations is further complicated by limited data on the age and developmentally associated alterations in the clearance of busulfan and other chemotherapy conditioning regimens.
Several studies have evaluated the impact of weight extremes -under or overweight -in adults receiving hematopoietic stem cell transplants. 6, 9, 10 However, few studies have addressed the impact of BMI extremes in children receiving HSCT. The aim of this study was to assess the effect of BMI upon transplant outcomes in pediatric recipients of bone marrow transplants for hematologic malignancies.
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Patients and Methods

Data Sources
The compliance is monitored by onsite audits. The CIMBTR maintains an extensive database of detailed patient-, transplant-, and disease-related information, and prospectively collects data longitudinally with yearly follow-ups. 11 Observational studies conducted by the CIBMTR are performed in compliance with HIPAA regulations as a public health authority and also in compliance with all applicable federal regulations pertaining to the protection of human research 15 The sample size of this cohort allowed inclusion of patients in the threshold percentiles by adding groups at risk for underweight or overweight, which could demonstrate a possible dose-effect relationship of BMI and outcome.
Study Endpoints and Variables
Primary endpoints were transplant related mortality (TRM), relapse, relapse-free survival (RFS), and overall survival (OS). Variables analyzed included recipients' weight according to ageadjusted BMI as the main effect. Other variables included age, gender, performance score, race, disease risk, time from diagnosis to transplant, year of transplant, HLA match and donor type (according to Weisdorf et al 16 ), marrow cell dose, CMV status, GVHD prophylaxis, and conditioning regimen
Statistical Analysis
Overall survival and leukemia-free survival were calculated using Kaplan-Meier estimates.
Cumulative incidence analysis was used to describe treatment related mortality and relapse. 
RESULTS
Patient Characteristics
There were 3687 children who met the eligibility criteria. Clinical features of this study population are shown in Table 1 . Median age ranged from 10-13 years. Of these, 282 (7.2%) were UW, 509 (13.8%) were at RUW, 1880 (56.8%) were normal weight, 573 (15.5%) were at OW, and 443 (12%) were OB. The distribution of age groups was similar in patients in the overweight groups. Among OW and OB patients, 56.8% were transplanted for ALL, but again, there were no significant differences in BMI distributions among the diagnoses. However, the OB group had a higher number of patients with ALL (63%), unrelated donor recipients (56%), and from transplant centers in the United States (61%). There were no significant differences in BMI distributions across donor types, conditioning, cell doses, or GVHD prophylaxis ( Table 2) . There were 1,194 patients who received BuCy containing regimens and 2,493 who received CyTBI regimens.
Transplant Related Mortality (TRM)
Cumulative incidences of three year TRM ranged from 18% (95% Confidence Interval [CI] 13-22) to 28% (95% CI, 24-32, p<0.001) from the lower to the higher BMI groups (figure 1a).
Multivariate analysis of TRM adjusted for significant variables revealed relative risk (RR) of 1.28 (95% CI 1.05-1.56, p=0.014) in OB patients compared to children with normal weight (Table 2) .
However, the overall p-value in the TRM model was 0.12. Other variables that predicted higher RR of TRM included age 10-18 yrs vs 2-9 yrs (p<.001), non-white race (<0.001), time from diagnosis to transplant >12 months (p=0.013), and year of BMT 1990-1998 (p<0.001).
There were no statistically significant differences among BMI groups in 100 day mortality. Of patients in the OB group, 16% died within day 100 of non-relapse causes, and 10-13% in the accounted for 57% and 40% of early deaths (<100d) in patients in the OW and OB groups respectively (Supplemental Table 1 ).
Relapse
Cumulative incidences of three year disease relapse ranged from 33% (95% CI 28-39) to 21% (95% CI, 17-25, p<0.001) from the lower to the higher BMI groups (figure 1b). Multivariate analysis revealed lower relative risk of relapse for both OW and OB groups ( Table 2 ).
Decreased relapse was also observed in patients who had female donors or sex mismatched donors (p=.0016), time to transplant <12 months (p=0.017), and well matched unrelated donor (p<.0001).
Relapse-free and Overall Survival
There were no significant differences in either RFS or OS among the weight groups (Table 3 , Fig 1c, 1d ). Multivariate analysis for treatment failure (1-RFS) and overall mortality showed superior survival for younger age, performance score >90, white race, time to BMT <12 months, and matched sibling donor recipients.
Patients in the US and Canada
As the largest proportion of obese children (61%) who received a BMT were from the US and Canada a subset analysis in this population was pursued. Table 3 outline these results and demonstrate a significant higher TRM (RR 1.44, 95% CI, 1.14-1.83, p<0.001) among obese children compared to children normal BMI. Other results in this subset were comparable to the larger group.
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Chemotherapy Dosage Adjustments
Dose information was available for 1016 OW and OB patients (Supplemental Table 2 ). Only 13.1% of patients appeared to have dose adjustments; most patients were >10 years. Of patients with dose adjustments, 80% were >10 kg over IBW. There were no statistically significant differences between the groups with and without dose adjustments in TRM, relapse, RFS, or OS.
DISCUSSION
The effects of obesity on allogeneic transplant outcomes in children have not been well elucidated. In this large registry based analysis of 3687 pediatric patients, we observed that overweight children experienced decreased incidence of relapse, a trend towards higher TRM and no significant difference in RFS and OS compared to other BMI groups. There was also no effect of underweight BMI on outcomes, and all analyses were adjusted for other covariates, such as year of transplant and HLA matching that have been shown previously to be significantly associated with the risks of treatment related mortality and relapse. This finding is in contrast to studies of weight extremes in children with leukemias, in which weight extremes are associated with an increased relapse risk and increased mortality. 17, 18 There are a few HSCT studies in children with findings that contrast to ours. A single institutional retrospective study by Bulley et al. demonstrated inferior OS in OB patients. 19 In this study of 324 children, 17% were OW, but the study population comprised a diverse group of diagnoses, stem cell sources, and conditioning regimens. Almost half of the patients in the OB group had non-malignant diseases. The OB group had inferior OS, event-free survival (EFS), and higher early TRM compared to patients with normal weight. Dose adjustments were performed in 41% of the 54 OB children. Two recent studies assessed the impact of weight extremes with allogeneic HSCT in more homogenous populations. A study of children
transplanted for severe aplastic anemia by Barker et al. found that obese patients had a higher probability of grades III-IV acute GVHD (relative risk of 1.55) compared to normal weight patients. 20 In addition, TRM at day 100 was higher in OB patients: 29% compared to 12% for normal weight patients, and OB patients had worse OS, with an increase in TRM. This study included various intensities of multiple conditioning regimens and donor sources, and dose adjustments for OB were not analyzed. A series of children receiving unrelated cord blood transplants noted that 37% of 200 children had age adjusted BMI >85% 19 . There were no differences in any of the outcomes measured, including time to engraftment, TRM, DFS, and OS when the OW or OB patients were compared with normal weight patients. The conditioning regimens were uniform, and included either busulfan or TBI, and chemotherapy dose adjustments were consistently done for patients >125% IBW.
Obesity is now considered an independent prognostic factor for non-relapse mortality in an adult HSCT specific comorbidity index (HCT CI), with a hazard ratio of 1.9. 21 In adults, obesity is associated with other important comorbidity including heart disease and diabetes. We investigated the number of reported comorbidities in this study and 13% of cases had reported at least one comorbidity, most commonly, asthma, pulmonary conditions other than asthma and seizures. The presence of the reported comorbidities in this pediatric population was not correlated with any BMI group. The American Society of Clinical Oncology recently published guidelines for chemotherapy dosing for obese adult patients. 22 These recommendations note that there is no evidence that short or long term toxicities are increased with non-adjusted dosing and recommend full weight based chemotherapy dosing. However, studies of the effects of obesity upon outcomes in adults have been limited by diverse conditioning regimens, diseases, and stem cell sources; the majority of studies comprise autologous transplants. 27 Survival among patients 85-95% and <85%
ideal body weight was significantly worse. Considering the degree of variability across studies, in adults and children, with malignant and nonmalignant diseases there is an impact of obesity on post transplant outcomes.
The effect of obesity on pharmacokinetics of drug metabolism has not been well studied in children. In adults, drug absorption is rarely affected by obesity, but drug distribution may vary with differences in kidney and liver blood flow with diminished clearance. 5 Busulfan is the drug most studied in the BMT setting, which is not surprising given the routine use of pharmacokinetics for dosing. A retrospective study of oral busulfan in children by Dupuis et al.
noted no significant effect of obesity upon busulfan dose requirements. 28 Browning et al.
recently reported a retrospective study of pharmacokinetics in children who received an IV busulfan test dose in a reduced intensity conditioning regimen using actual weight to determine dose. 29 Pharmacokinetic data from both the test dose and regular dose were available for 19 patients with BMI >85%. Children with high BMI had higher AUCs when dosed on actual body weight compared with children with normal or low BMI and needed less drug to reach goal AUC.
Although data on the clinical use of busulfan pharmacokinetics in patients in this study is not available, the absence of these data likely have modest effect on the study conclusions since multivariable modeling demonstrated no association between study endpoints and conditioning regimen. For this reason, the analyses were not restricted to TBI containing regimens.
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More recent pediatric transplant protocols are consistent in the approach to dose adjustment.
Children's Oncology Group protocols for leukemia transplants now mandate chemotherapy adjustments for children with ABW >125% IBW, and the multi-institutional COBLT study used chemotherapy dosing based on 40% adjusted ideal body weight. 20 In addition to chemotherapy dosing, cell dose may be an important factor in outcome. Surprisingly, there was no significant difference in cell doses among the BMI groups. Low cell doses may increase TRM, 31 and marrow cell doses >3.6 x 10 8 /kg may accelerate engraftment, decrease severe acute GVHD, and improve leukemia free survival. 32 Our data demonstrate that age is significantly associated with risk of treatment related mortality and relapse. These data are consistent with the increased risk of treatment related mortality and relapse in older adolescent patients with acute leukemia. In addition, the risks of treatment related mortality and relapse in the older adolescent population appear similar to those reported in a recent comparison between adolescents and young adults and older adults transplanted for acute myeloid leukemia. However, given the heterogeneity of diagnoses and conditioning regimens in our cohort, additional analyses will be required to evaluate fully the impact of increasing age on the risk of treatment related mortality and relapse.
Subset analysis on children receiving transplant in the US or Canada was performed to
further analyze the impact of obesity, as most obese children were reported from centers in these countries. When enriching the population with greater number of obese children the relationship between BMI and TRM became clear. The multivariate analysis of TRM including all patients was not significant, even though the RR was higher for the obese group. Among
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This study is the largest to date of the effect of BMI upon transplant outcomes in children. The large sample size, uniform stem cell source, and restriction of subjects to hematologic malignancies and myeloablative conditioning lend credence to the results. Our study demonstrates that children who are overweight who receive allogeneic BMT for hematologic malignancies do not have worse RFS or OS than normal or underweight children; the increase in TRM is off-set by a decreased risk of relapse; this may comprise a doseresponse effect requiring further study. There are obvious limitations to the study, with heterogenous approaches to GVHD prophylaxis and other supportive care, as well as insufficient data regarding intended chemotherapy doses and actual administered doses.
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